Association Between Statin Use and Intracerebral Hemorrhage Location: A Nested Case-Control Registry Study. (7th March 2023)

• Record Type: Journal Article
• Authors: Boe, Nils Jensen; Hald, Stine Munk; Jensen, Mie Micheelsen; Bojsen, Jonas Asgaard; Elhakim, Mohammad Talal; Florisson, Sandra; Saleh, Alisa; Clausen, Anne; Möller, Sören; Harbo, Frederik Severin Gråe; Graumann, Ole; Hallas, Jesper; García Rodríguez, Luis Alberto; Al-Shahi Salman, Rustam; Goldstein, Larry B.; Gaist, David
• Is Part Of: Neurology. Volume 100:Number 10(2023)
• Page Start: e1048
• Page End: e1061
• Publication Date: 2023-03-07
• Subjects: Neurology -- Periodicals; Neurology -- Periodicals; Neurologie -- Périodiques; 616.8
• DOI: 10.1212/WNL.0000000000201664
• Languages: English
• ISSNs: 0028-3878

Abstract

Abstract : Background and Objectives: A causal relationship between statin use and intracerebral hemorrhage (ICH) is uncertain. We hypothesized that an association between long-term statin exposure and ICH risk might vary for different ICH locations. Methods: We conducted this analysis using linked Danish nationwide registries. Within the Southern Denmark Region (population 1.2 million), we identified all first-ever cases of ICH between 2009 and 2018 in persons aged ≥55 years. Patients with medical record–verified diagnoses were classified as having a lobar or nonlobar ICH and matched for age, sex, and calendar year to general population controls. We used a nationwide prescription registry to ascertain prior statin and other medication use that we classified for recency, duration, and intensity. Using conditional logistic regression adjusted for potential confounders, we calculated adjusted ORs (aORs) and corresponding 95% CIs for the risk of lobar and nonlobar ICH. Results: We identified 989 patients with lobar ICH (52.2% women, mean age 76.3 years) who we matched to 39, 500 controls and 1, 175 patients with nonlobar ICH (46.5% women, mean age 75.1 years) who we matched to 46, 755 controls. Current statin use was associated with a lower risk of lobar (aOR 0.83; 95% CI, 0.70–0.98) and nonlobar ICH (aOR 0.84; 95% CI, 0.72–0.98). Longer duration of statin use was also associated with a lower risk of lobar (<1 year: aOR 0.89; 95% CI, 0.69–1.14; ≥1 year to <5 years aOR 0.89; 95% CI 0.73–1.09; ≥5 years aOR 0.67; 95% CI, 0.51–0.87; p for trend 0.040) and nonlobar ICH (<1 year: aOR 1.00; 95% CI, 0.80–1.25; ≥1 year to <5 years aOR 0.88; 95% CI 0.73–1.06; ≥5 years aOR 0.62; 95% CI, 0.48–0.80; p for trend <0.001). Estimates stratified by statin intensity were similar to the main estimates for low-medium intensity therapy (lobar aOR 0.82; nonlobar aOR 0.84); the association with high-intensity therapy was neutral. Discussion: We found that statin use was associated with a lower risk of ICH, particularly with longer treatment duration. This association did not vary by hematoma location.